Literature DB >> 23532201

[Use and interpretation of the number needed to treat in urological practice].

L A Kluth1, M Rink, S F Shariat, F K Chun, M Fisch, P Dahm.   

Abstract

The number needed to treat (NNT) is a useful way for clinicans to describe the benefit or harm of a treatment as well as the costs involved. When interpreting the NNT it is essential to use the NNT in a clinically equivalent and appropriate setting. When evaluating the consequences of a treatment clinicians should make sure that the patients being treated have the same risk profile asthe study patients. Differences in duration of follow-up and baseline risks can cause significant changes in the NNT; therefore, NNT should be evaluated in addition to relative risk differences and baseline risk to reduce any ambivalence in the assessment of a treatment. This review provides insights into the assessment and clinical use of NNT in the practice.

Entities:  

Mesh:

Year:  2013        PMID: 23532201     DOI: 10.1007/s00120-013-3149-x

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  11 in total

1.  Absolutely relative: how research results are summarized can affect treatment decisions.

Authors:  L Forrow; W C Taylor; R M Arnold
Journal:  Am J Med       Date:  1992-02       Impact factor: 4.965

2.  Evidence-based medicine: a survey of American Urological Association members.

Authors:  Roger L Sur; Charles D Scales; Glenn M Preminger; Philipp Dahm
Journal:  J Urol       Date:  2006-09       Impact factor: 7.450

3.  An assessment of clinically useful measures of the consequences of treatment.

Authors:  A Laupacis; D L Sackett; R S Roberts
Journal:  N Engl J Med       Date:  1988-06-30       Impact factor: 91.245

4.  Evidence based purchasing: understanding results of clinical trials and systematic reviews.

Authors:  T Fahey; S Griffiths; T J Peters
Journal:  BMJ       Date:  1995-10-21

5.  Prostate-cancer mortality at 11 years of follow-up.

Authors:  Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Stefano Ciatto; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Hans Lilja; Marco Zappa; Louis J Denis; Franz Recker; Alvaro Páez; Liisa Määttänen; Chris H Bangma; Gunnar Aus; Sigrid Carlsson; Arnauld Villers; Xavier Rebillard; Theodorus van der Kwast; Paula M Kujala; Bert G Blijenberg; Ulf-Hakan Stenman; Andreas Huber; Kimmo Taari; Matti Hakama; Sue M Moss; Harry J de Koning; Anssi Auvinen
Journal:  N Engl J Med       Date:  2012-03-15       Impact factor: 91.245

6.  Same information, different decisions: the influence of evidence on the management of hypertension in the elderly.

Authors:  M Cranney; T Walley
Journal:  Br J Gen Pract       Date:  1996-11       Impact factor: 5.386

Review 7.  A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer.

Authors:  Joshua J Meeks; Joaquim Bellmunt; Bernard H Bochner; Noel W Clarke; Siamak Daneshmand; Matthew D Galsky; Noah M Hahn; Seth P Lerner; Malcolm Mason; Thomas Powles; Cora N Sternberg; Guru Sonpavde
Journal:  Eur Urol       Date:  2012-06-01       Impact factor: 20.096

8.  A randomized comparison of patients' understanding of number needed to treat and other common risk reduction formats.

Authors:  Stacey L Sheridan; Michael P Pignone; Carmen L Lewis
Journal:  J Gen Intern Med       Date:  2003-11       Impact factor: 5.128

9.  Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.

Authors:  H Barton Grossman; Ronald B Natale; Catherine M Tangen; V O Speights; Nicholas J Vogelzang; Donald L Trump; Ralph W deVere White; Michael F Sarosdy; David P Wood; Derek Raghavan; E David Crawford
Journal:  N Engl J Med       Date:  2003-08-28       Impact factor: 91.245

10.  Medical doctors' perception of the "number needed to treat" (NNT). A survey of doctors' recommendations for two therapies with different NNT.

Authors:  Peder Andreas Halvorsen; Ivar Sønbø Kristiansen; Olaf Gjerløw Aasland; Olav Helge Førde
Journal:  Scand J Prim Health Care       Date:  2003-09       Impact factor: 2.581

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.